论文部分内容阅读
目的评价拉米夫定、恩替卡韦治疗慢性重型乙型肝炎的短期疗效。方法72例慢性重型乙型肝炎患者随机分为拉米夫定组42例和恩替卡韦组30例。拉米夫定组给予拉米夫定100 mg,每天1次口服,恩替卡韦组给予恩替卡韦0.5 mg,每天1次,两组的基础护肝治疗相同,共治疗24周。结果恩替卡韦治疗组血清HBV DNA的阴转率为60%,明显高于拉米夫定组,且丙氨酸转氨酶、总胆红素水平均明显好于拉米夫定组(P<0.05)。结论短期应用恩替卡韦治疗慢性重型乙型肝炎疗效明显优于拉米夫定。
Objective To evaluate the short-term efficacy of lamivudine and entecavir in the treatment of chronic severe hepatitis B Methods Seventy - two patients with chronic severe hepatitis B were randomly divided into lamivudine group (n = 42) and entecavir group (n = 30). Lamivudine group given lamivudine 100 mg orally once daily, entecavir group entecavir 0.5 mg once daily, the two groups of the same treatment of liver protection, a total of 24 weeks. Results The seroconversion rate of serum HBV DNA in entecavir treatment group was 60%, which was significantly higher than that of lamivudine group. The levels of alanine aminotransferase and total bilirubin were significantly better than lamivudine group (P <0.05). Conclusion Short-term use of entecavir in the treatment of chronic severe hepatitis B is significantly better than lamivudine.